Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.68 |
| ▸ | RAB9A | P51151 | 9/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.66 |
| ▸ | RELA | Q04206 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 3/20 | 0.62 |
| ▸ | MITF | O75030 | 2/20 | 0.62 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.62 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15504852 | 1.00 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL15513654 | 0.81 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL12612162 | 0.81 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL7032483 | 0.80 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL15513845 | 0.79 | ADORA3 (0.50) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL12612180 | 0.79 | ADORA3 (0.50) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL13171376 | 0.78 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2TP53KDM4E | |
| SCHEMBL15504851 | 0.76 | TDP1 (0.60) | NPC1RAB9ASMN1; SMN2KDM4ENFKB1 | |
| SCHEMBL15514419 | 0.76 | TDP1 (0.60) | NPC1RAB9ASMN1; SMN2KDM4ENFKB1 | |
| SCHEMBL13171377 | 0.73 | NPC1 (0.83) | NPC1RAB9ASMN1; SMN2TP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-9878999-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20140073650-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | PSMB3, PSME3, PSMD3 | NPC1 2728/4885RAB9A 3319/4885SMN1; SMN2 3198/4885 |
| US-20140073650-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | PSMB3, PSME3, PSMD3 | NPC1 2728/4885RAB9A 3319/4885SMN1; SMN2 3198/4885 |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | PSMB3, PSME3, PSMD3 | NPC1 2728/4885RAB9A 3319/4885SMN1; SMN2 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.